A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices


  • Jorge E. Valenzuela M.D.,

    Corresponding author
    • Gastroenterology Section, Department of Medicine, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles, California 90033
    Search for more papers by this author
  • Timothy Schubert,

  • M. Ronald Fogel,

  • Richard M. Strong,

  • Joel Levine,

  • Peter R. Mills,

  • Thomas L. Fabry,

  • Linda W. Taylor,

  • Harold O. Conn,

  • James T. Posillico

  • The members of the multicenter study group were: Thomas Colturie, Jacob Korula, Norman D. Grace, Patrick H. Griffin, Eugene E. Schiff, Loren Laine, from the Los Angeles County-University of Southern California Medical Center and Rancho Los Amigos Hospital, Los Angeles, CA; University of Missouri, Kansas City, MO; University of Louisville, Louisville, KY; Jerry L. Pettis Memorial Veterans Hospital, Loma Linda, CA; University of Colorado Health Sciences Center, Denver, CO; Medical College of Virginia, Richmond, VA; University of Michigan, Ann Arbor, MI; Veterans Administration Medical Center, Miami, FL; Faulkner & Lemuel Shattuck Hospitals, Boston, MA; St. Luke's/Roosevelt, New York, NY, and Serono Laboratories, Randolph, MA.


A prospective, randomized, placebo-controlled, double-blind, multicenter clinical trial of intravenous somatostatin (Stilamin®; Serono Laboratories, Inc., Randolph, MA) was performed in 102 patients with actively bleeding esophageal varices from August, 1985, to November, 1986. Patients had major hemorrhage indicated by hematemesis or melena and evidence of significant blood loss. For entry, patients had to have endoscopic demonstration of active bleeding from esophageal varices or stigmata of recent hemorrhage and bright red blood in the gastric aspirate with no other source of bleeding found. Randomized patients received identical appearing somatostatin or placebo for a 30-hr study period. Those given somatostatin received a 250-μg bolus and a 250-μg per hr infusion with repeat bolus and doubling of the infusion if the bleeding was not controlled. In retrospect, 18 patients could not be evaluated.

Of the 84 evaluable patients, 48 received somatostatin and 36 placebo. They were comparable in age, gender, severity of liver disease and history of variceal bleeding. Transfusion requirements were similar in both groups. Bleeding stopped for 12 consecutive hr during 30 hr of the study period in 31 (65%) of the somatostatin group vs. 30 (83%) of the placebo group (p = 0.06). The median time to cessation of bleeding was 2 hr in the placebo group and 3 hr in the somatostatin group. Deaths following the study period were nine (25%) in the placebo group and 15 (31%) in the somatostatin group. Within the limitations of the present study, we conclude that somatostatin was ineffective in the management of active bleeding of esophageal varices.